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Abstract
Objectives The aim of the study was to investigate whether the osteoinductive properties of bone-conditioned medium (BCM)
harvested from cortical bone chips within a clinically relevant short-term period can enhance the biologic characteristics of
deproteinized bovine bone mineral (DBBM) in vitro.
Materials and methods To assess the biofunctionalization of DBBM, the adhesive, proliferative, and differentiation properties of
mesenchymal stromal ST2, pre-osteoblastic MC3T3-E1, and primary bone-derived cells grown on BCM-coated DBBM were
examined by crystal violet staining of adherent cells, BrdU ELISA, and qRT-PCR, respectively.
Results BCM extracted within 20 min or 24 h in either Ringer’s solution (BCM-RS) or RSmixed with autologous serum (BCM-
RS + S) increased the adhesive properties of all three cell types seeded on DBBM. The 20-min BCM-RS preparation appeared
more potent than the 24-h preparation. BCM-RS made within 20 min or 24 h had strong pro-proliferative effects on all cell types
grown on DBBM. RS + S alone exhibited a considerable pro-proliferative effect, suggesting an impact of the serum on cellular
growth. DBBM coated with BCM-RS or BCM-RS + S, made within 20 min or 24 h each, caused a significant induction of
osteogenic differentiation marker expression with a higher potency of the BCM-RS + S. Finally, a strong additive effect of fresh
bone chips combined with BCM-coated DBBM on the osteogenic differentiation of the three cell types was observed.
Conclusions Altogether, the data strongly support the biofunctionalization of DBBM with BCM extracted within a clinically
relevant time window of 20 min.
Clinical relevance Pre-activation of non-osteoinductive biomaterials with BCM, prepared from autologous bone chips
during a guided bone regeneration (GBR) procedure, bears the potential of an optimal treatment modality for bone defects
in daily practice.
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Introduction
Reconstruction of maxillofacial and oral bone defects might
represent a clinical challenge that requires the use of bone
substitutes [1]. The indications for using bone grafts range
from minor fenestration defects to bridging major continuity
defects in the facial skeleton. Despite the advances in the
generation of new bone substitute materials, autografts are
largely considered as the gold standard in osseous reconstruc-
tive surgery [2–4]. Indeed, bone derived from the patient own
body is the only bone graft that possesses osteogenic,
osteoinductive, and osteoconductive properties, thus provid-
ing viable osteogenic precursor cells, growth factors as well
as physical scaffolding structure to foster new bone forma-
tion, and revascularization of the augmented volume [5].
Furthermore, recent laboratory-based evidence supports a
paracrine function of the autogenous bone realized through
a spectrum of secretory proteins [6] that possess the potential
to target cellular processes in various cell types actively
supporting the graft consolidation process in vivo [7–9].
Although autografts are considered superior for their
consolidation, harvesting requires technical expertise and,
depending on the need for an additional harvesting site,
can be associated with increased surgical time, hematoma,
postoperative pain, neurovascular injury, increased risk of
infection, and esthetic deformity at the graft extraction site
[10–12]. In addition, often intraoral sites do not provide
sufficient quantities of bone for a grafting medium on large
alveolar defects [11]. To overcome the shortcomings of the
autograft alone, a guided bone regeneration (GBR) tech-
nique utilizing a combination of autologous bone chips
with a bone graft substitute, such as deproteinized bovine
bone mineral (DBBM), and a bioabsorbable collagen
membrane was developed [13–15]. The two (autologous
and xenogenic) bone fillers, a combination termed com-
posite graft, are applied either in two layers or mixed.
This bone augmentation technique has been successfully
applied for a number of indications including early implant
placement with simultaneous contour augmentation in the
esthetic zone [3, 16–18], horizontal and vertical bone aug-
mentation called sausage technique [19, 20], and for sinus
floor elevation procedures in the posterior maxilla [21]. In
addition, the GBR technique using a 2-layer composite
graft has demonstrated good long-lasting stability of the
peri-implant hard and soft tissues, and excellent esthetic
outcomes [3, 18, 22].
The DBBM applied in the GBR procedure combines
good osteoconductivity with a low substitution rate [23,
24]. In addition, the lack of organic matrix makes DBBM
fully biocompatible, showing minimal risks for foreign body
reactions in patients [25, 26]. However, the processing limits
the biological activity of the DBBM, namely its osteogenic
and osteoinductive properties. To address this limitation, the
paracrine function of the autograft has been utilized in the
GBR by pre-hydration of the DBBM and collagen mem-
branes with bone-conditioned medium (BCM) [27–29].
BCM is a mixture of patient’s own blood and physiological
solution enriched with autogenous growth factors [30].
These growth factors are released from autologous bone
chips harvested from an intraoral site and stored in the mix-
ture of autologous blood and saline for the time of the sur-
gical site and implant bed preparation.
Recently, our laboratory has revealed part of the biological
mechanisms that underlie the successful outcomes from GBR
procedures utilizing BCM derived from autologous bone
[6–9, 31–33]. It has been demonstrated that the technique by
which the autologous bone chips are harvested may signifi-
cantly influence the cellular viability and the release of growth
factors [34]. BCM extracted from bone scraper or bone mill
samples has revealed significantly higher expression of
growth factors such as vascular endothelial growth factor
(VEGF) and bone morphogenetic protein-2 (BMP-2) com-
pared to samples prepared by piezosurgery or bone drilling
[34, 35]. Moreover, higher amounts of newly formed bone in
association with autografts harvested by bone mill compared
to grafts harvested by bone scraper or piezosurgery were also
demonstrated in a histomorphometric study in vivo using a
minipig model [36].
More recently, we have shown that the time frame for the
BCM extraction from cortical bone affects the BCM compo-
sition and the behavior of osteoprogenitors treated with it [33].
In particular, we have demonstrated a significant and very fast
release of transforming growth factor-β1 (TGF-β1) from au-
togenous bone chips within 10 min versus a delayed BMP-2
release from 40 min on. BCMs harvested within short terms
(10, 20, or 40 min), corresponding to the typical time of a
surgical procedure, significantly enhanced the proliferative
capacity and collagen matrix production of BCM-treated
osteoprogenitors. BCMs extracted within longer periods (1,
3, or 6 days) exhibited a great capacity to induce the later
stages of osteoblast differentiation and matrix mineralization
due to the combined activity of TGF-β1 and BMP-2.
As a clinically relevant translation of these investiga-
tions, we hypothesized that short-term coating of DBBM
with short-term extracted BCM potentiates the beneficial
properties of the biomaterial. More specifically, the aim of
the present study was to investigate whether the biological
activity of the BCM can be transferred onto the DBBM
in vitro, leading to induced osteogenic properties of mes-
enchymal stromal cells, pre-osteoblastic cells, and primary
human bone-derived cells. The study further aimed to in-
vestigate if a synergy between BCM-coated DBBM and
freshly harvested bone chips could be detected, thus pro-
viding justification for a clinical approach combining au-
tologous bone, BCM, and DBBM, which would complete-
ly utilize the osteoinductive properties of the autograft.
Clin Oral Invest
Materials and methods
BCM preparation and DBBM coating
The preparation of BCM was described previously [30]. In
brief, cortical bone chips from the buccal side of fresh pig
mandibles (Slaughterhouse: Küng Metzgerei, Toffen,
Switzerland) were harvested by using a bone scraper (Hu-
Friedy, Rotterdam, the Netherlands) and soaked in extracting
solutions for 20 min or 24 h (Fig. 1a). Extracting solutions,
consisting of either Ringer’s solution (RS) or RS mixed with
autologous serum (RS + S) in a 1:1 ratio, were supplemented
Fig. 1 Increased adhesive properties of bone-related cell cultures grown
on BCM-coated DBBM. a Schematic representation of the experimental
set-up utilized throughout the study. The following steps are illustrated:
(1) harvesting of cortical bone chips (BCh) from the buccal side of fresh
pigmandibles using a bone scraper; (2)mixing of the BChwith extracting
solutions consisting of Ringer’s solution (RS) or a 1:1mixture of Ringer’s
solution and autologous serum (RS + S); (3) incubation of the resulting
mixtures for 20 min or 24 h during which time release of molecules from
the BCh occurs; (4) harvesting of two types of bone-conditioned medium
(BCM) labeled as BCM-RS and BCM-RS + S; (5) coating of
deproteinized bovine bone mineral (DBBM) with the respective BCM
preparations for 10 min prior to (6) cell seeding and growth. b, c
Adhesion rate of ST2,MC3T3-E1, and primary bone–derived cells plated
on DBBM coated with BCM-RS (b) or BCM-RS + S (c) prepared within
20 min or 24 h each. Controls (Ctrl) represent cells of each cell type
seeded on BCM-free DBBMhydrated with RS or RS + S. Adhesion rates
were assessed by crystal violet assay at 1, 3, and 6 h. Experimental values
were normalized to the values obtained for the total number of seeded
control cells, taken as 100% adhesion. Means ± SD from three indepen-
dent experiments and significant differences to control cells at each time
point unless otherwise indicated, ***P < 0.001, **P < 0.01, *P < 0.05 are
shown
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with 1% antibiotics/antimycotics (AA; ThermoFisher
Scientific, Basel, Switzerland). A ratio of 1 g bone chips per
2 ml medium (50% weight/volume) was utilized. Two types
of media, abbreviated BCM-RS and BCM-RS + S, were col-
lected from three independent preparations. The BCMs were
sterile filtered and kept frozen at − 80 °C until experimental
cell seeding.
DBBM (Geistlich Bio-Oss®) granules in the 0.25–1-mm
range size were kindly provided by Geistlich Pharma
(Wolhusen, Switzerland). Prior to cell seeding, 35 or 200 mg
of DBBM granules (resulting in a layer of a 3-mm height)
were placed on the bottom of 96- or 24-well ultra-low attach-
ment plates (Corning, NY, USA), respectively, and coated for
10 min with each of the BCM preparations. Cells seeded on
BCM-free DBBM, pre-hydrated with RS or RS + S, were
used as controls (Ctrl) throughout the study. Corning® ultra-
low attachment plates were our product of choice among three
different brands tested because it ensured 0% cell attachment
on the plastic surface even after coating with BCM.
A 3D-culturing system was also adopted in the present
study. DBBM granules in the 24-well culture system were
prepared as described above, and coated with either RS + S
or the 20-min BCM-RS + S preparation. Immediately after
cell seeding, a Nunc™ polycarbonate cell culture insert
(ThermoFisher Scientific) with a 0.4-μm pore size was placed
in the cell culturing well and filled with 0.5 g of fresh bone
chips as depicted in Fig. 7a.
Cell culture
Mesenchymal stromal ST2 cells derived from mouse bone
marrow were obtained from RIKEN Cell Bank (Tsukuba,
Japan). Pre-osteoblastic MC3T3-E1 cells derived from a
C57BL/6 mouse calvaria were obtained from ECACC collec-
tion (Sigma-Aldrich, Buchs, Switzerland). Both cell lines
were grown in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal calf serum (FCS;
Invitrogen, Zug, Switzerland) and 1% AA (ThermoFisher
Scientific). Cells were starved in 0.3% FCS/DMEM for 24 h
before culturing on DBBM.
Primary human bone–derived cells were obtained from
three donors using a modification of previously described
techniques [37]. Fresh bone particles harvested from the
retromolar area using a bone scraper were retrieved from
anonymous and systemically healthy individuals, who had
undergone implant placement with GBR procedure at the
Department of Oral Surgery and Stomatology, following
signed informed consent and approval by the Ethics
Committee, Bern, Switzerland. In brief, after extensive wash-
ing in excess of sterile PBS for complete removal of blood and
dislodged cells, the bone chips were digested using 0.2% col-
lagenase type II (Worthington Biochemical Corporation,
Lakewood, NJ, USA) in Hanks’ balanced salt solution for
30 min, in a humidified atmosphere of 5% CO2 at 37 °C.
Complete culturing medium was used to stop the enzymatic
reaction and specimens were placed into a gentleMACS™ C
Tube (Miltenyi Biotec, Solothurn, Switzerland).
GentleMACS Dissociator (Miltenyi Biotec) was used for au-
tomated dissociation of the specimens to obtain a single-cell
suspension. The suspension was subsequently passed through
Falcon® 70 μm Cell Strainer (Corning) before culturing in
complete minimum essential medium Eagle–alpha modifica-
tion (α-MEM; Thermo Fischer Scientific) supplemented with
10%FCS and 1%AA. Cells that had not undergonemore than
five passages were starved in 0.3% FCS/α-MEM for 24 h
before culturing on DBBM. Data in each data set were obtain-
ed from three independent experiments performed with pri-
mary bone–derived cells from three different cell donors.
Characterization of the primary human bone–derived cultures,
according to published classifications [38, 39] and in compar-
ison with the ST2 and MC3T3-E1 strains, revealed them as a
mixture of cells with osteoblastic and preosteocytic phenotype
(Electronic Supplementary Material, Figure S1). However, no
expression of sclerostin, which is considered as a marker of
mature osteocytes, was detected in any of the three cell types.
For differentiation experiments followed byRNA analyses,
complete media were supplemented with 50 μg/mL ascorbic
acid (Invitrogen, Zug, Switzerland) and 2 mM β-
glycerophosphate (Invitrogen) as it was described
previously [33].
Cell adhesion assay
The adhesion capacity of ST2, MC3T3-E1, and primary
bone–derived cells cultured on BCM-coated DBBM was de-
termined by crystal violet (Sigma-Aldrich) staining of adher-
ent cells. In brief, 5 × 104 cells/well were plated in duplicate,
in complete medium on DBBM in ultra-low attachment 96-
well plates and allowed to adhere for 1, 3, and 6 h. To test for a
potential background staining produced by the BCM-coated
DBBM, no cell controls were included in the assay (Electronic
Supplementary Material, Figure S2a). After removal of cul-
ture medium, cells were extensively washed 3 times in PBS in
order to remove any non-adherent cells, then fixed in 4%
paraformaldhyde (PFA; Sigma-Aldrich) for 20 min at room
temperature (RT), and stained with crystal violet solution
(0.1%; Sigma-Aldrich) in PBS for 30 min at RT. After 8
washing cycles in deionized H2O to remove crystal violet
excess, the dye bound to adherent cells was solubilized using
a 10% (volume/volume) acetic acid (Sigma-Aldrich) on an
orbital shaker at 150 rpm for 5 min at RT. The absorbance
of the eluate was measured at 570 nm using an EL808 reader
(BioTek Instruments GmbH, Lucerne, Switzerland). To ob-
tain a value for the total number of seeded cells as well as to
correct for the background signal produced by the BCM, cells
of each experimental group were processed in parallel in the
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following way: After removal of the culture medium, cells
were directly fixed in 4% PFA omitting the 3 cycles of exten-
sive wash in PBS. The rest of the procedure was performed as
described above. Please, refer to the Electronic Supplementary
Material, Figure S2b for more details on the quantitative as-
sessment of the background staining produced by the BCM.
Experimental values corrected for the background signal were
normalized to the values obtained for the total number of
seeded control cells, which were allowed to settle down for
1 h and processed as described above (conditionally taken as
100% adhesion). Data represent means ± SD from three inde-
pendent experiments performed with each of the three cell
types, in duplicates.
Cell proliferation assay
Proliferation rates of cultured on BCM-coated DBBM ST2,
MC3T3-E1, and primary bone–derived cells were determined
using a 5-bromo-20-deoxyuridine (BrdU) incorporation ELISA
(Roche, Basel, Switzerland) as described [40]. In brief, after
starvation of 24 h, cells were plated in triplicate at 1 × 103
cells/well, in 3% FCS-containing medium on DBBM in black
ultra-low attachment 96-well plates and allowed to proliferate
for 0, 24, 48, 72, and 96 h before a 2-h labeling with BrdU.
Incorporation of BrdU into newly synthesized DNAwas deter-
mined according to the manufacturer’s protocol using an
Infinite® 200 luminometer (Tecan, Männedorf, Switzerland).
Experimental values were normalized to the values of control
cells at the time point 0. Data represent means ± SD from three
independent experiments performed with each of the three cell
types, in triplicates.
RNA analysis by quantitative reverse transcription-
polymerase chain reaction
For RNA analyses, cells were plated at 2.5 × 105 cells/well, in
differentiation medium on DBBM in ultra-low attachment 24-
well plates. Total RNA from cells grown on BCM-coated
DBBM in the absence or in the presence of fresh bone chips
(Fig. 7a) for 1, 3, and 7 days was isolated using Trizol
(Thermo Fisher Scientific) according to the manufacturer’s
protocol. The extracted RNA was additionally purified by
using the RNeasy MinElute Cleanup Kit (Qiagen, Basel,
Switzerland). RNA, quantified on a NanoDrop 2000c instru-
ment (ThermoFisher Scientific), was reverse transcribed and
relative transcripts for collagen type I (Col1a1), runt-related
transcription factor 2 (Runx2), alkaline phosphatase (Alpl),
and osteocalcin (or bone gamma-carboxyglutamate protein
2, Bglap2) genes, normalized to Gapdh, were measured using
FastStart Universal SYBR Green Master ROX (Roche), and
the primer sequences listed in Electronic Supplementary
Material, Tables S1 and S2. The two tables include four addi-
tional osteogenic marker genes that were used in the
characterization of the primary human bone–derived cells
(for more detai ls , please refer to the Electronic
Supplementary Material, Figure S1). For simplicity, the same
non-capitalized symbols were used for both mouse and human
genes throughout the paper except in Table S2, where human
gene symbols were capitalized. qPCR was carried out in a
QuantStudio 3 instrument (Applied Biosystems, Rotkreuz,
Switzerland) using a standard thermal cycling profile. The
efficiency ΔΔCt method [41] was used to calculate gene ex-
pression levels normalized to Gapdh values and calibrated to
values of controls at day 1. All samples were run in duplicates.
Data represent means ± SD from three independent experi-
ments performed with each of the three cell types.
Statistical analysis
All grouped data are means ± SD. Statistical analysis was
performed using GraphPad InStat Software (GraphPad, La
Jolla, CA, USA), version 3.05. Multiple comparisons were
completed using one-way analysis of variance (ANOVA)
with Tukey’s post hoc test. Values of P < 0.05 were consid-
ered significant.
Results
Increased adhesive properties of bone-related cell
cultures grown on BCM-coated DBBM
Figure 1a depicts the experimental set-up used throughout
the study. Bone chips harvested from the buccal side of
fresh pig mandibles were mixed with either RS or RS +
S. The resulting BCMs, BCM-RS and BCM-RS + S, ex-
tracted for either 20 min or 24 h each, were used for a short
10 min-coating of DBBM prior to cell seeding and growth
for different time intervals.
We first investigated the adhesive properties of the mesen-
chymal stromal ST2, pre-osteoblastic MC3T3-E1, or primary
human bone–derived cells seeded either on control BCM-free
DBBM hydrated with RS or RS + S, DBBM coated with the
20-min BCM preparation, or DBBM coated with the 24-h
BCM preparation. The BCMs were made in each of the two
diluents, RS (Fig. 1b) or RS + S (Fig. 1c). Adhesion was
followed over 1, 3, and 6 h using crystal violet assay. The
results showed that in comparison to controls, BCM extracted
within 20 min in RS significantly (P < 0.01) increased the
adhesive properties of all three cell types seeded on DBBM
(Fig. 1b).With few exceptions, the 24-h BCM-RS preparation
also caused significant (P < 0.05) increase in the adhesive po-
tential of the three cell types seeded on DBBM. Interestingly,
in all three cell types, the 20-min BCM preparation appeared
to be more potent than the 24-h preparation (compare red with
blue bars, P < 0.05).
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A similar behavior was detected for cells seeded on DBBM
coated with BCM-RS + S prepared for either 20 min or 24 h
(Fig. 1c). However, the 20-min BCM preparation appeared to
be significantly more potent than the 24-h preparation in the
case of MC3T3-E1 pre-osteoblasts (P < 0.05) at each time
point and in the case of the primary bone–derived cells
(P < 0.01) at 1 and 6 h. Interestingly, control cells seeded on
BCM-free DBBM pre-coated with RS + S (dark gray bars,
Fig. 1c) were characterized with higher but not significant
relative adhesion values compared to control cells seeded on
DBBM pre-hydrated with RS (light gray bars, Fig. 1b). This
suggests that to a certain extent, serum proteins along with
BCM contribute to the increased adhesive properties of the
investigated cell types.
Pro-proliferative properties of bone-related cell cul-
tures grown on DBBM coated with BCM-RS
We further evaluated the proliferative rate of ST2, MC3T3-
E1, and primary bone–derived cells grown on BCM-coated
DBBM (Fig. 2). Compared to control cells grown on DBBM
hydrated with RS, cells grown on DBBM coated with BCM-
RS preparations made within 20 min or 24 h showed a strong
increase in BrdU uptake into newly synthesized DNA until a
confluence was reached (Fig. 2a). Compared to the respective
controls, the detected increase was in the range of 3.9–4.5-fold
for ST2 and MC3T3-E1 cell lines and 6.0–7.5-fold for the
primary bone–derived cultures grown on the BCM-coated
DBBM. Most importantly, the short-term 20-min BCM
preparation was as potent as the 24-h preparation except for
ST2 cells after 24 h of growth, at which time point the 24-h
BCM preparation exhibited a significantly higher (P < 0.05)
proliferative rate than the 20-min preparation.
In contrast to the effects caused by the BCM-RS-coated
DBBM, no significant differences in the proliferative rates
of control cells grown on DBBM hydrated with RS + S and
cells grown on DBBM coated with BCM-RS + S preparations
made within 20 min or 24 h were detected for any of the three
cell types over 5 days (Fig. 2b). Notably, for each of the three
cell types, the growth rates of control cells seeded on RS + S-
coated DBBM were considerably higher (in the range of 3.1–
6.9-fold) compared to control cells seeded on RS-hydrated
DBBM (Fig. 2a and b). This finding suggests a significant
impact of the serum on the proliferative ability of the three
cell types, which may be further extrapolated to the patient’s
own blood used to store the autologous bone chips during the
surgical tooth bed preparation.
BCM-coated DBBM induces osteogenic differentiation
of bone-related cell cultures
As a next step, we investigated the expression of osteogenic
differentiation markers such as Col1a1 (Fig. 3), Runx2
(Fig. 4), Alpl (Fig. 5), and Bglap2 (Fig. 6) in cells grown on
BCM-coated DBBM for 1, 3, and 7 days. DBBM coated with
BCMmade within 20min or 24 h, in each of the two solutions
(RS or RS + S), caused a significant increase in Col1a1
(Fig. 3) and Runx2 (Fig. 4) mRNAs above the levels
Fig. 2 Proliferative properties of
bone-related cell cultures grown
on BCM-coated DBBM. a, b
Proliferative ability of ST2,
MC3T3-E1, and primary bone–
derived cells grown on DBBM
coated with BCM-RS (a) or
BCM-RS + S (b), was assessed by
BrdU incorporation into newly
synthesized DNA immediately
after plating (0 h) as well as at 24,
48, 72, and 96 h. Cells of each cell
type grown on BCM-free DBBM
that is hydrated with RS (a) or RS
+ S (b) are used as controls (Ctrl).
Experimental values were nor-
malized to the values of control
cells at the time point 0. Means ±
SD from three independent ex-
periments and significant differ-
ences to control cells unless oth-
erwise indicated, ***P < 0.001,
**P < 0.01, *P < 0.05 are shown
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expressed and detected in control cells grown on DBBM pre-
hydrated with the diluents alone. The qRT-PCR analyses
showed two clear trends. First, a tendency of a higher potency
exhibited by the 20 min compared to the 24-h BCM prepara-
tion, especially inMC3T3-E1 and primary bone–derived cells
(Figs. 3 and 4) as well as for individual time points in the ST2
cells grown on BCM-RS + S–coated DBBM (Fig. 3b and 4b),
was observed. Second, a consistent fashion of a higher poten-
cy exhibited by the DBBM coated with BCM-RS + S in all
three cell types was observed (refer to the difference in the
scales between a and b in Figs. 3 and 4). Following a signif-
icant increase at days 1 and 3, Col1a1 expression at day 7
Fig. 3 BCM-coated DBBM
induces Col1a1 gene expression
in bone-related cell cultures. a, b
ST2, MC3T3-E1, and primary
bone–derived cells were grown
on DBBM coated with BCM-RS
(a) or BCM-RS + S (b) for 1, 3,
and 7 days before total RNA was
isolated and analyzed for Col1a1
expression by qRT-PCR.
Controls (Ctrl) represent cells of
each cell type seeded on BCM-
free DBBM hydrated with RS (a)
or RS + S (b). Values normalized
to Gapdh are expressed relative to
the values of control cells at the
“1 day” time point. Please note
the differences in the scales of the
y-axis. Data represent means ±
SD from three independent ex-
periments. Significant differences
to the respective controls at day 1
unless otherwise indicated,
***P < 0.001, **P < 0.01,
*P < 0.05
Fig. 4 BCM-coated DBBM
induces Runx2 gene expression in
bone-related cell cultures. a, b
ST2, MC3T3-E1, and primary
bone–derived cells were grown
on DBBM coated with BCM-RS
(a) or BCM-RS + S (b) for 1, 3,
and 7 days before total RNA was
isolated and analyzed for the ex-
pression of the transcription factor
gene Runx2 by qRT-PCR.
Controls (Ctrl) represent cells of
each cell type seeded on BCM-
free DBBM hydrated with RS (a)
or RS + S (b). Values normalized
to Gapdh are expressed relative to
the values of control cells at the
“1 day” time point. Please note
the differences in the scales of the
y-axis. Data represent means ±
SD from three independent ex-
periments. Significant differences
to the respective controls at day 1
unless otherwise indicated,
***P < 0.001, **P < 0.01,
*P < 0.05
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marked a decrease to the expression levels detected on day 1.
In contrast, the expression of Runx2 generally reached a pla-
teau at day 3, and thus remained high at day 7 (Fig. 4).
Compared to Col1a1 and Runx2, Alpl (Fig. 5) and Bglap2
(Fig. 6) genes showed a slightly different pattern of upregu-
lated expression in cells grown on BCM-coated DBBM
compared to control cells, with a clear trend of continuous
upregulation over 7 days. However, with a small exception
for Alpl expression in MC3T3-E1 cells at day 7, we detected
no significant differences in the potential of the two BCM
preparations (20 min vs. 24 h) to upregulate the mRNA levels
of the two osteogenic differentiation markers (Figs. 5 and 6).
Fig. 5 BCM-coated DBBM
induces Alpl gene expression in
bone-related cell cultures. a, b
ST2, MC3T3-E1, and primary
bone-derived cells were grown on
DBBM coated with BCM-RS (a)
or BCM-RS + S (b) for 1, 3, and
7 days before total RNA was iso-
lated and analyzed for the ex-
pression of the osteogenic marker
gene Alpl by qRT-PCR. Controls
(Ctrl) represent cells of each cell
type seeded on BCM-free DBBM
hydrated with RS (a) or RS + S
(b). Values normalized to Gapdh
are expressed relative to the
values of control cells at the
“1 day” time point. Please note
the differences in the scales of the
y-axis. Data represent means ±
SD from three independent ex-
periments. Significant differences
to the respective controls at day 1
unless otherwise indicated,
***P < 0.001, **P < 0.01,
*P < 0.05
Fig. 6 BCM-coated DBBM
induces Bglap2 gene expression
in bone-related cell cultures. a, b
ST2, MC3T3-E1, and primary
bone–derived cells were grown
on DBBM coated with BCM-RS
(a) or BCM-RS + S (b) for 1, 3,
and 7 days before total RNA was
extracted and analyzed for the
expression of the osteogenic
marker gene Bglap2 by qRT-
PCR. Controls (Ctrl) represent
cells of each cell type seeded on
BCM-free DBBM hydrated with
RS (a) or RS + S (b). Values nor-
malized to Gapdh are expressed
relative to the values of control
cells at the time point “1 day.”
Please note the differences in the
scales of the y-axis. Data repre-
sent means ± SD from three in-
dependent experiments.
Significant differences to the re-
spective controls at day 1 unless
otherwise indicated,
***P < 0.001, **P < 0.01,
*P < 0.05
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The trend of a higher potency exhibited by the DBBM coated
with BCM-RS + S preparations remained (refer to the
difference in the scales between a and b in Figs. 5 and 6).
Altogether, the results suggest that DBBM adsorbs and
accumulates factors contained in the BCM that influence both
early and late stages of the differentiation process. The process
is governed by the upregulated transcription factor Runx2,
which characterizes osteoprogenitors and orchestrates the next
steps of the osteogenic process, accompanied by the increased
expression of Col1a1 and Alpl characterizing pre-osteoblasts,
and finally by the upregulated osteoblast marker Bglap2.
Additive effect of fresh bone chips and BCM-coated
DBBM on the osteogenic differentiation of bone-
related cell cultures
Often, the GBR technique utilizes a combination of autolo-
gous bone, DBBM, and a collagen barrier membrane [3,
16–18, 21, 42]. To create an in vitro set-up that mimics as
close as possible the clinical situation, we compared the dif-
ferentiation potential of ST2, MC3T3-E1, and primary bone–
derived cells grown under four different conditions: (1) con-
trol (Ctrl) condition, consisting of cells grown on BCM-free
DBBM pre-coated with RS + S; (2) BCM condition,
consisting of cells grown on DBBM coated with the 20-min
BCM-RS + S preparation; (3) bone chips (BCh) condition,
consisting of cells grown as in (1) but in the presence of fresh
bone chips; and (4) BCM/BCh condition, consisting of cells
grown in the combined presence of BCM-coated DBBM and
fresh bone chips (Fig. 7a). The fresh bone chips in conditions
(3) and (4) were placed in a cell culture insert with a 0.4-μm
pore size, which allows transport of molecules released by the
bone chips but no cell migration.
The expression of the osteogenic differentiation markers
Col1a1 (Fig. 7b), Runx2 (Fig. 7c), Alpl (Fig. 8a), and
Bglap2 (Fig. 8b) in cells grown under the above listed condi-
tions for 1, 3, and 7 days was analyzed by qRT-PCR.
Generally, both BCM applied as a coating on DBBM (red
bars) and fresh bone chips combined with BCM-free DBBM
(light green bars) caused increased expression of each of the
four differentation markers in all three cell types (Figs. 7 and
8). Interestingly, whereas there were no significant differences
between the individual effects of BCM and fresh bone chips,
there was an additive and in most of the cases extremely sig-
nificant (P < 0.001) effect of fresh bone chips combined with
BCM-coated DBBM on the osteogenic gene expression at all
three time points (dark green bars). The combined effect of the
fresh bone chips and BCM applied as a coating on the bioma-
terial appeared to be more than additive on the expression of
(1) Col1a1 at day 7 in the primary bone–derived cells
(Fig. 7b), (2) Runx2 at day 7 in MC3T3-E1 cells (Fig. 7c),
(3) Alpl at all three time points in ST2 cells as well as at days 3
and 7 inMC3T3-E1 and primary bone–derived cells (Fig. 8a),
and (4) Bglap2 at days 3 and 7 in MC3T3-E1 and the primay
bone–derived cells (Fig. 8b). In contrast to Cola1a gene ex-
pression, where the cumulative increase reached a plateau at
day 3 (Fig. 7b), we observed a continuous and very significant
upregulation in the expression of Runx2 (Fig. 7c), Alpl
(Fig. 8a), and Bglap2 (Fig. 8b) over the entire 7-day period.
In summary, the reported data demonstrate a strong addi-
tive effect of fresh bone chips combined with BCM-coated
DBBM on the osteogenic differentiation of the three cell types
utilized in the present study. This justifies the simultaneous
application of BCM-coated DBBM and autologous bone
chips leading to the complete utilization of the osteoinductive
properties of the autograft.
Discussion
DBBM is a calcium phosphate–based bone substitute of nat-
ural origin, widely used in dental surgery for bone augmenta-
tion procedures and for the treatment of periodontal and peri-
implant bone defects [43–45]. By nature, DBBM is a bovine
bone undergoing a chemical extraction process at low heat
(300 °C) for removing existing organic components while
the natural architecture of bone remains preserved [46].
Whereas some alloplastic materials exhibit considerably high
elastic moduli, DBBM has an elastic modulus close to that of
mandibular cortical bone [47, 48]. In vivo, it is nearly
nonresorbable [49]. DBBM is one of the most researched
bone grafting materials, which has demonstrated excellent
osteoconductive properties positively influencing the bone re-
generation [50–52]. Furthermore, it has been shown to suc-
cessfully adsorb a variety of proteins, including BMPs, thus
generating favorable microenvironment for migrating mesen-
chymal stem cells and osteoprogenitors [53, 54]. Aiming to
maximize the adsorption of factors released in the BCM to a
bone grafting material, we made the choice to utilize DBBM
in the current in vitro study. Previous studies have demonstrat-
ed that a 24-h extraction of cortical bone chips of porcine
origin with cell culture media contains a large spectrum of
proteins (more than 150) [6] possessing the potential to target
cellular processes in various cell types playing a role in the
graft consolidation process [7–9, 32]. In particular, the BCM
improved oral fibroblast cell activity [7, 8] as well as induced
osteoclastogenesis in bone marrow cultures [9]. It can be sug-
gested that BCM resembles other autogenous growth factor
sources such as platelet-rich fibrin (PRF) or platelet-rich plas-
ma (PRP). However, a number of studies have shown a lim-
ited ability of the platelet concentrates to induce bone forma-
tion [55–58]. This may be explained by the fact that the
growth factors contained in PRF and PRP originate from
whole blood, whereas BCM represents an autologous growth
factor-rich medium originating from bone tissue and aiming to
accelerate the regeneration of the same tissue. Therefore,
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BCM is thought to exhibit a specific activity in bone augmen-
tation. Indeed, it has been proven that BCM triggers a prom-
inent response of TGF-β signaling pathways by modulating
the expression of adrenomedulin (ADM), pentraxin 3 (PTX3),
BTB/POZ domain-containing protein 11 (BTBD11),
interleukin-11 (IL-11), NADPH oxidase 4 (NOX4), and pro-
teoglycan 4 (PRG4), all known downstream regulators of the
TGF-β signaling cascade [8]. Various functions associated
with bone metabolism and graft consolidation have been
reported for each of the genes in this panel [8]. Moreover,
our most recent research identifies TGF-β1 and BMP-2, two
growth factors with a specific activity in bone regeneration, as
major constituents of BCM [33]. Most importantly, a fast and
significant release of TGF-β1 from autogenous bone was de-
tected within 10 min and a specific crosstalk between TGF-β1
and BMP-2 was pointed as the mechanism by which BCM
exerts its activity on the osteogenic differentiation of mesen-
chymal stromal cells [33].
Fig. 7 Additive effect of fresh bone chips and BCM-coated DBBM on
the Col1a1 and Runx2 gene expression in bone-related cell cultures. a
Schematic representation of the four experimental conditions, which are
compared in (b). ST2, MC3T3-E1, and primary bone–derived cells are
grown for 1, 3, and 7 days either on (1) BCM-free DBBM granules
hydrated with RS + S, a condition labeled as control (Ctrl) or (2)
DBBM granules coated with BCM prepared within 20 min in RS + S, a
condition labeled as BCM. Experimental conditions (3) bone chips (BCh)
and (4) BCM/BCh duplicate conditions (1) and (2) in the presence of
fresh bone chips placed in a cell culture insert with a 0.4-μm pore size.
b, c Effect of BCM-coated DBBM in the absence or presence of fresh
bone chips on Col1a1 (b) and Runx2 (c) mRNA expression levels in ST2,
MC3T3-E1, and primary bone–derived cells. Cells were grown under
each of the four experimental conditions described in (a) for 1, 3, and
7 days before total RNA was isolated and analyzed by qRT-PCR. Values
normalized toGapdh are expressed relative to the values of control cells at
the “1 day” time point. Please note the differences in the scales of the y-
axis. Data represent means ± SD from three independent experiments.
Significant differences to the respective controls at day 1 unless otherwise
indicated, ***P < 0.001, **P < 0.01, *P < 0.05
Clin Oral Invest
Thus, the goal of the current study was to take a next step in
investigating the biological activity of BCM by combining it
with DBBM. Our data strongly suggest that bio-activation of
osteoconductive bone substitutes with a short-term extracted
BCM is possible. Osteogenesis is characterized by recruitment
of osteoprogenitors, their attachment, proliferation, and differ-
entiation into mature osteoblasts [59]. Indeed, bone-related cell
types grown on DBBM coated with BCM, which was prepared
within a clinically relevant time window of 20 min, exhibited
increased adhesive, proliferative, and differentiation properties.
To the best of our knowledge, this is the first study that gives a
rationale for the fast preparation of BCM during the surgical
implant bed preparation and its application for coating of bio-
materials. Moreover, we observed an additive, nearly synergis-
tic effect of fresh bone chips combined with BCM-coated
DBBM on the osteogenic differentiation of the three cell types
utilized in the study. This further supports the simultaneous
application of BCM-coated DBBM and autologous bone chips
in GBR procedures. In comparison to the present study where
BCM was applied as a coating on DBBM, it is interesting to
note that an opposing effect of BCM on the osteogenic differ-
entiation of ST2 cells was observed with BCM applied in sus-
pension, in the absence of a biomaterial [31, 33]. This observa-
tion was valid for both BCM preparations, 20-min and 24-h.
Peng et al. detected decreased alkaline phosphatase activity and
mRNA expression in ST2 cells treated with a 24-h BCM prep-
aration [31], and we observed an inhibitory effect of the 20-min
BCM preparation applied in suspension on the expression of
late osteogenic markers [33]. We can thus speculate that
proteins contained in the BCM may exhibit differential confir-
mation when coated on DBBM or another biomaterial. This
new confirmation may be differentially recognized by trans-
membrane receptors on the cell surface leading to activation
of signaling pathways different from the ones activated by pro-
teins contained in a suspension. Altogether, our data strongly
support a clinical approach combining the excellent adsorption
and osteoconductive properties of the DBBMwith two sources
of autogenous growth factors, namely BCM and autologous
bone chips. Furthermore, BCM is extracted in a mixture of
Ringer’s solution and patient blood, which adds the activity
of factors from yet a third autogenous source to the BCM.
Indeed, BCM-RS + S preparations were more potent in induc-
ing the osteogenic differentiation of the tested cell types. RS + S
in itself was enough to stimulate cellular proliferation but not
osteogenesis. The topic of blood coating of biomaterials is
poorly investigated and deserves further attention. A study re-
ports differential positive effects of titanium implant surface
coating with different blood components on the proliferative
potential of human osteoblasts [60]. The differences that we
observed in the effects caused by the DBBM coated with the
20-min or the 24-h BCM preparation were with variable signif-
icance for the various cellular functionalities tested in the study.
This may be attributed to the specific protein content and pro-
tein stability of the different BCM preparations and deserves
further investigation.
A number of studies have reported combination ap-
proaches utilizing bone substitutes and recombinant growth
factors. BMP-2, BMP-7, platelet-derived growth factor
Fig. 8 Additive effect of fresh
bone chips and BCM-coated
DBBM on the Alpl and Bglap2
gene expression in bone-related
cell cultures. a, b Effect of BCM-
coated DBBM in the absence or
presence of fresh bone chips on
Alpl (a) and Bglap2 (b) mRNA
levels in ST2, MC3T3-E1, and
primary bone–derived cells. Cells
were grown under each of the four
experimental conditions de-
scribed in Fig. 7a for 1, 3, and
7 days before total RNA was ex-
tracted and analyzed by qRT-
PCR. Values normalized to
Gapdh are expressed relative to
the values of control cells at the
time point “1 day.” Please note
the differences in the scales of the
y-axis. Data represent means ±
SD from three independent ex-
periments. Significant differences
to the respective controls at day 1
unless otherwise indicated,
***P < 0.001, **P < 0.01,
*P < 0.05
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(PDGF), fibroblast growth factor-2 (FGF-2), and growth and
differentiation factor-5 (GDF-5) are among the growth factors
commonly researched and utilized in regenerative dentistry
[61–67]. Terheyden et al. combined DBBM of the same type
as the used in the current study with BMP-7 and compared this
combination with DBBM alone in maxillary sinus floor
grafting in pigs [61]. The authors reported that significant
amounts of new bone were generated in both groups with
the important exception that the BMP-7-coated DBBM group
resulted in faster apposition and better quality of bone.
Shortcomings of utilizing recombinant growth factors for clin-
ical practice have been their short half-lives, instability and
fast degradation rates, side effects, and not on a last place poor
cost-effectiveness [68–71].
The approach of utilizing a combination of BCM-coated
DBBM and autologous bone chips, described in the current
study, would revoke the necessity of extracting a huge amount
of autologous bone chips allowing an intraoral rather than an
extraoral donor site to be used for autograft harvesting. This
will further decrease the postoperative morbidity at the patient
donor site and contribute to a reduced healing time. Combined
with previous findings about the biological activity of the BCM
[33], the current study represents the first steps towards the
establishment of an in vitro-tested standard procedure for gen-
eration of BCM as well as for pre-coating of DBBM with it,
within the limited time for the surgical tooth bed preparation.
A limitation of the present study is the use of BCM of
porcine origin. Future research employing transcriptomics
and proteomics analyses of RNA and protein extracted from
cells grown on DBBM coated with human BCM is needed in
order to determine the genes, on a genome-wide base, whose
expression have been modulated in response to short-term
extracted human BCM. These additional investigations
would supplement the data presented in the current study by
investigating the signaling pathways of osteogenesis trig-
gered by the BCM-activated biomaterial. Furthermore, rec-
ommendation stemming from in vitro studies in the form of a
protocol for the preparation of BCM and its application for
biofunctionalization of DBBM in GBR procedures would
need an animal testing in vivo. Such studies will determine
whether BCM combined with a bone grafting material may
be a superior candidate for bone regeneration procedures than
the individual recombinant growth factors combined with the
respective bone graft.
In summary, the presented in vitro study clearly demon-
strates that biological pre-activation of DBBM with BCM,
extracted within a clinically relevant time window of
20 min, is feasible and may appear as an optimal modality in
the treatment of both regular and complex bone defects.
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